This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Agile Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Agile Therapeutics şirketinin toplam hissedar öz sermayesi $-21.9M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $15.0M ve $36.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.85m
Eşitlik	-US$21.91m
Toplam yükümlülükler	US$36.88m
Toplam varlıklar	US$14.96m

Son finansal sağlık güncellemeleri

Recent updates

Agile appoints chief commercial officer from within ranks amid leadership revamp

Oct 10

How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?

Feb 25

Agile Therapeutics issues cash projection at JP Morgan healthcare conference

Jan 14

Assessing Agile Therapeutics

Jan 10

How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?

Jan 04

Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch

Nov 30

Agile Therapeutics EPS in-line

Nov 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AGRX negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: AGRX şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AGRX borçsuzdur.

Borcun Azaltılması: AGRX 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AGRX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: AGRX un, serbest nakit akışı her yıl % 2.1 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

This company has been acquired

Agile Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nasdaq to Suspend Common Stock of Agile Therapeutics Effective March 26

Agile Therapeutics Announces Update on Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Agile Therapeutics Receives an Additional 180-Day Period, or Until September 25, 2023 from Nasdaq, to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Agile Therapeutics, Inc. Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Agile Therapeutics, Inc. Contemplates Bankruptcy

Agile Therapeutics, Inc. Contemplates Bankruptcy

Recent updates

Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others.

Agile Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $15 million.

Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. (OTCPK:AGRX) for $10.7 million.

Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index

Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index

Nasdaq to Suspend Common Stock of Agile Therapeutics Effective March 26

Agile Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Agile Therapeutics, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023

Agile Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Agile Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Agile Therapeutics Announces Update on Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Agile Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023

Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX).

Agile Therapeutics Receives an Additional 180-Day Period, or Until September 25, 2023 from Nasdaq, to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Agile Therapeutics, Inc. has completed a Follow-on Equity Offering.

Agile Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Agile Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Agile appoints chief commercial officer from within ranks amid leadership revamp

Agile Therapeutics Announces Reorganization of Leadership Team

Agile Therapeutics, Inc. Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Agile Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Agile gains as H.C. Wainwright sees 630% upside potential

Agile Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.

Agile Therapeutics prices $24M upsized stock offering

Agile Therapeutics, Inc. to Appoint Jason Butch as Principal Financial Officer

Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation

Agile Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

Agile Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy

Agile Therapeutics, Inc. Contemplates Bankruptcy

Agile Therapeutics: Bullish On Capitulation And Max Pain

Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy

Agile Therapeutics, Inc.(NasdaqCM:AGRX) dropped from Russell 3000E Growth Index

Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting

Agile Therapeutics, Inc. Contemplates Bankruptcy

How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?

Agile Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

New 90-day high: US$3.12

Agile Therapeutics issues cash projection at JP Morgan healthcare conference

Assessing Agile Therapeutics

How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?

Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System

Agile Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 3 Secure Study Results for Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Contraception

Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch

Agile Therapeutics EPS in-line

Agile Therapeutics, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Agile Therapeutics, Inc. to Report Q2, 2020 Results on Aug 11, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin